New Advances of Dopaminergic Agonists for Treatment of Parkinsons Disease
10.3870/j.issn.1004-0781.2001.02.002
- VernacularTitle:多巴胺受体激动药治疗帕金森病的新进展
- Author:
Sun BIN
- Publication Type:Journal Article
- From:
Herald of Medicine
2001;(2):77-79
- CountryChina
- Language:Chinese
-
Abstract:
Parkinson's disease (PD) caused by the deficiency of DA in the substantial nigra-striatum system in the brain is a chronically progressive disease. Early diagnosis and prompt treatment PD can prolong work time and improve life quality of the patient. There are three primary approaches to increase activity of dopaminergic system:vicarious treatment to compensate DA; promote releasing DA in nerve endings of dopamine neurons and to prevent decreasing DA metabolism,as well as application of agonists that stimulate dopamine receptors. Some specialists suggest that application of dopaminergic agonists in the initial stage can not only delay the occurrence of syndrome on side effects with long-term use of levodopa,but also prevent the damage of dopaminergic cell caused by levodopa or its metabolite,and delay the development of PD. There are positive and adverse effects with DA agonists. This paper discussed the usage and side effects of classic and new dopaminergic agonists.
